@inproceedings{afnan-etal-2026-exploring,
    title = "Exploring Novel Drug Research Area using Large Language Models Based on Research Trends in Biomedical Literature",
    author = "Afnan, Afnan  and
      Van Supranes, Michael  and
      Nishiyama, Tomohiro  and
      Wakamiya, Shoko  and
      Aramaki, Eiji",
    editor = "Demner-Fushman, Dina  and
      Ananiadou, Sophia  and
      Roberts, Kirk  and
      Tsujii, Junichi",
    booktitle = "{B}io{NLP} 2026",
    month = jul,
    year = "2026",
    address = "San Diego, California",
    publisher = "Association for Computational Linguistics",
    url = "https://preview.aclanthology.org/ingest-acl-workshops/2026.bionlp-1.81/",
    pages = "997--1013",
    ISBN = "979-8-89176-434-7",
    abstract = "The rapid expansion of biomedical literature makes manual identification of novel drug-disease relationships increasingly difficult. Existing approaches have leveraged LLMs to mine abstracts or construct knowledge graphs for drug repurposing. There are two key limitations: finite context windows for capturing macro-level research trends, and single-pass black-box pipelines make it difficult to verify outputs. This paper proposes a pipeline for discovering new drug targets by combining disease and drug research trends using Large Language Models (LLMs). Our method extracts PICO components from PubMed abstracts, normalizing the Population and Intervention Component to ICD and ATC codes, respectively. A temporal frequency delta matrix is constructed to capture publication count shifts across 2013 to 2022, then used to discover novel drug areas. Compared with the abstract-based baseline, our approach showed qualitative signs of generating combinations that were more closely aligned with observed research trends and, in some cases, more clinically plausible. These findings suggest the potential usefulness of structured trend information for LLM-based exploration, although the differences between the two methods were limited and the results remain preliminary. Future work will focus on validating the consistency and reliability of these candidates."
}